Migraine trials in Poland

In Poland 11 Also abroad 249

11 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
Where
Cracow, Poznan, Wrocław
Age
6 years to 17 years
People
2,100 worldwide
Run by
Pfizer
See details and how to joinNCT04649242 · EU 2024-512743-23-00
Phase 3Taking people
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
Where
Cracow, Poznan, Wroclaw
Age
6 years to 17 years
People
600 worldwide
Run by
Pfizer
See details and how to joinNCT04743141 · EU 2024-512744-32-00
Phase 3Taking people
A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine
Where
Bydgoszcz, Cracow, Lublin, Oswiecim, Warsaw, Wrocław
Age
12 years to 17 years
People
285 worldwide
Run by
H. Lundbeck A/S
See details and how to joinNCT04965675 · EU 2024-510656-13-00
Phase 3Taking people
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
Where
Cracow, Katowice, Lublin, Poznan, Warsaw, Wroclaw, Wrocław
Age
6 years to 17 years
People
640 worldwide
Run by
Pfizer
See details and how to joinNCT05156398 · EU 2024-512382-13-00
Phase 3Taking people
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
Where
Bydgoszcz, Cracow, Lublin, Oswiecim, Warsaw, Wrocław
Age
6 years to 17 years
People
600 worldwide
Run by
H. Lundbeck A/S
See details and how to joinNCT05164172 · EU 2022-502917-27-00
Phase 3Taking people
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
Where
Krakow, Lublin, Oświęcim, Warsaw
Age
6 years to 17 years
People
315 worldwide
Run by
H. Lundbeck A/S
See details and how to joinNCT05897320 · EU 2022-502538-14-00
Phase 3Taking people
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
Where
Bydgoszcz, Cracow, Poznan, Warsaw, Wrocław
Age
12 years to 17 years
People
420 worldwide
Run by
AbbVie
See details and how to joinNCT06810505 · EU 2024-513836-28-00
Phase 3Taking people
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Where
Bydgoszcz, Cracow, Lublin, Poznan, Warsaw, Wroclaw
Age
6 years to 17 years
People
450 worldwide
Run by
AbbVie
See details and how to joinNCT05711394 · EU 2022-501100-94-00
Phase 3Taking people
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
Where
Cracow, Katowice, Lublin, Oswiecim, Warsaw, Wroclaw
Age
18 years to 45 years
People
723 worldwide
Run by
Pfizer
See details and how to joinNCT06641466 · EU 2024-517121-10-00
No phaseTaking people
Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
Where
Wroclaw
Age
18 years and over
People
700 worldwide
Run by
Hospital Universitari Vall d'Hebron Research Institute
See details and how to joinNCT07159750
Phase 3Enrolling by invitation
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Migraine
Where
Bydgoszcz, Cracow, Lublin, Poznan, Warsaw, Wroclaw
Age
6 years to 17 years
People
650 worldwide
Run by
AbbVie
See details and how to joinNCT05707949 · EU 2022-501099-24-00